IRLAB Therapeutics Valuation Multiples

IRLAB Therapeutics Overview

About IRLAB Therapeutics

IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on innovative treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds which aims at offering improved clinical benefit for patients with Parkinson's disease. The company’s current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.

Founded

2013

HQ

Employees

18

Website

irlab.se

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $8M

EBITDA: ($8M)

EV

$9M

Valuation Multiples

Multiples.vc

Start free trial

IRLAB Therapeutics Financials

IRLAB Therapeutics reported last 12-month revenue of $8M and negative EBITDA of ($8M).

In the same LTM period, IRLAB Therapeutics generated ($8M) in EBITDA losses and had net loss of ($10M).

IRLAB Therapeutics P&L

In the most recent fiscal year, IRLAB Therapeutics reported revenue of $7M and EBITDA of ($10M).

IRLAB Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX

IRLAB Therapeutics Stock Performance

IRLAB Therapeutics has current market cap of $14M, and enterprise value of $9M.

IRLAB Therapeutics' stock price is $0.17.

IRLAB Therapeutics Valuation Multiples

IRLAB Therapeutics trades at 1.1x EV/Revenue multiple, and (1.1x) EV/EBITDA.

IRLAB Therapeutics Financial Valuation Multiples

As of April 18, 2026, IRLAB Therapeutics has market cap of $14M and EV of $9M.

Equity research analysts estimate IRLAB Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

IRLAB Therapeutics has a P/E ratio of (1.5x).

IRLAB Therapeutics Margins & Growth Rates

IRLAB Therapeutics' revenue in the last 12 month grew by 51%.

IRLAB Therapeutics' revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.9M for the same period.

IRLAB Therapeutics' rule of 40 is 36% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

IRLAB Therapeutics' rule of X is 141% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

IRLAB Therapeutics Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

IRLAB Therapeutics M&A Activity

IRLAB Therapeutics acquired XXX companies to date.

Last acquisition by IRLAB Therapeutics was on XXXXXXXX, XXXXX. IRLAB Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

IRLAB Therapeutics Investment Activity

IRLAB Therapeutics invested in XXX companies to date.

IRLAB Therapeutics made its latest investment on XXXXXXXX, XXXXX. IRLAB Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).